Multiple Myeloma Posts on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

Is daratumumab plus RVd a good treatment for patients with newly diagnosed multiple myeloma in the long-term?

Is daratumumab plus RVd a good treatment for patients with newly diagnosed multiple myeloma in the long-term?

Posted by on May 6, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate the long-term safety and effectiveness of adding daratumumab (Darzalex) to RVd (lenalidomide/bortezomib/dexamethasone) therapy, followed by D-R (daratumumab/lenalidomide) maintenance for patients with newly diagnosed multiple myeloma (MM). The study found that this treatment was well tolerated...

Read More

Evaluating the combination of vorinostat with bortezomib and dexamethasone in relapsed myeloma.

Evaluating the combination of vorinostat with bortezomib and dexamethasone in relapsed myeloma.

Posted by on Apr 25, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effectiveness and safety of combining vorinostat (Zolinza) with bortezomib (Velcade) and dexamethasone (Decadron) in patients with relapsed multiple myeloma (MM). The data showed that the treatment combination had promising effectiveness but with side effects. Some background Multiple...

Read More

Is VD-PACE and immunotherapy a good salvage therapy for relapsed/refractory multiple myeloma?

Is VD-PACE and immunotherapy a good salvage therapy for relapsed/refractory multiple myeloma?

Posted by on Apr 11, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate if the VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) regimen in combination with immunotherapy was effective as a salvage therapy for patients with relapsed or refractory (r/r) multiple myeloma (MM). The study found this salvage therapy option...

Read More

Evaluating outcomes of daratumumab, pomalidomide, and dexamethasone followed by high dose chemotherapy and ASCT for unresponsive multiple myeloma.

Evaluating outcomes of daratumumab, pomalidomide, and dexamethasone followed by high dose chemotherapy and ASCT for unresponsive multiple myeloma.

Posted by on Apr 4, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the effectiveness of DPd (daratumumab, pomalidomide, and dexamethasone) as salvage therapy followed by high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for relapsed/refractory (RR) multiple myeloma (MM). The study concluded that this therapy is effective and well tolerated...

Read More

Evaluating factors associated with improved denosumab outcomes of patients with multiple myeloma

Evaluating factors associated with improved denosumab outcomes of patients with multiple myeloma

Posted by on Mar 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated factors associated with improved outcomes of denosumab (Xgeva) compared to zoledronic acid (Zometa).  The authors found that denosumab increased survival without cancer worsening in patients that planned to have an autologous stem cell transplant (ASCT) or those who previously received...

Read More

Evaluating the health-related quality of life in patients with multiple myeloma treated with daratumumab combined with bortezomib and dexamethasone.

Evaluating the health-related quality of life in patients with multiple myeloma treated with daratumumab combined with bortezomib and dexamethasone.

Posted by on Mar 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the health-related quality of life (HRQoL) for patients with relapsed/refractory (RR) multiple myeloma (MM) patients treated with D-Vd (daratumumab, bortezomib, and dexamethasone) compared to Vd (bortezomid and dexamethasone). The study showed that HRQoL did not decrease for 8 therapy cycles and long-term...

Read More

Is autologous stem cell transplant safe and effective for patients aged 75 or older with multiple myeloma?

Is autologous stem cell transplant safe and effective for patients aged 75 or older with multiple myeloma?

Posted by on Mar 6, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate the safety and effectiveness of autologous stem cell transplant (ASCT) in patients with multiple myeloma (MM) aged 75 or older. The study found that ASCT was safe and effective for certain patients in this age group. Some background MM is a type of blood cancer that impacts bone marrow. Therapy for...

Read More

Is CAR-T-cell therapy targeting BCMA safe and effective for patients with multiple myeloma?

Is CAR-T-cell therapy targeting BCMA safe and effective for patients with multiple myeloma?

Posted by on Mar 6, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate the safety and effectiveness of a type of chimeric antigen receptor (CAR)-T-cell therapy that targets B-cell maturation antigens (BCMA) for patients with multiple myeloma (MM). The study found that patients had a very good response to therapy, while there was a high risk of side...

Read More

Evaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.

Evaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.

Posted by on Feb 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study compared a combination therapy of carfilzomib (Kyprolis), lenalidomide (Revlimid), dexamethasone (Decadron), and cyclophosphamide (Cytoxan) to control combination therapies as an alternative treatment regimen in newly diagnosed patients with multiple myeloma (MM).   The authors concluded that this regimen provided very good...

Read More

Improved outcomes for relapsed/refractory multiple myeloma patients treated with daratumumab.

Improved outcomes for relapsed/refractory multiple myeloma patients treated with daratumumab.

Posted by on Feb 27, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effect of daratumumab (Darzalex)-based treatments on sustained minimal residual disease (MRD) negativity and outcomes in patients with relapsed/refractory (RR) multiple myeloma (MM). The data showed that treatments including daratumumab led to sustained MRD negativity and improved outcomes in these...

Read More

How do bortezomib, thalidomide, dexamethasone and daratumumab impact the quality of life of patients with multiple myeloma?

How do bortezomib, thalidomide,  dexamethasone and daratumumab impact the quality of life of patients with multiple myeloma?

Posted by on Feb 26, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the health-related quality of life of patients with multiple myeloma (MM) after treatment with VTd (bortezomib, thalidomide, and dexamethasone) with or without daratumumab (D; Darzalex). The study found that all patients that received treatment had an improved quality of life, while...

Read More